Table 2. . Retrospective studies comparing the performance of different radiologic criteria of response to sorafenib for the treatment of hepatocellular carcinoma.

Patients (n)	Analyzed criteria	First imaging follow-up	Main result	Other results	Ref.
60	RECIST, mRECIST, CHOI, EASL	2.1 months (range 1.0–6.2)	OS correlated only with response according to Choi criteria	–	[12]
190	RECIST, mRECIST	≤4 weeks	OS correlated with objective response (CR + PR) defined according to mRECIST but not according to RECIST 1.1	–	[26]
22	RECIST, mRECIST, CHOI, EASL, TV	8 ± 2 weeks	OS correlated only with response according to TV	–	[13]
64	RECIST, mRECIST, CHOI, EASL	2.1 months (range 1.4–3.0)	OS associated with objective response (CR + PR) defined according to Choi but not according to the other criteria	–	[11]
156	RECIST, mRECIST, RECICL	4–6 weeks	OS correlated only with categorization according to the RECICL	In patients categorized as SD or PD by RECIST1.1, only reclassification by RECICL was associated with OS	[25]
48	RECIST, mRECIST, EASL	4–6 weeks	Significant OS differences between PD and SD for all criteria, between PR and SD only for mRECIST and EASL	–	[24]
53	RECIST, mRECIST	4 and 8 weeks	Both methods provided good correlation with OS	In patients classified as SD according to RECIST, response according to mRECIST identifies a different prognosis	[23]

A particular attention was given to the correlation between overall survival (OS) and categorization of response according to each set of criteria.

EASL: European Association for the Study of the Liver; HCC: Hepatocellular carcinoma; mRECIST: Modified RECIST; PD: Progressive disease; PR: Partial response; RECICL: Response Evaluation Criteria in the Cancer of the Liver; RECIST: Response Evaluation Criteria in Solid Tumor; TV: Total volume measurement.